Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Nuvation Bio Inc (NUVB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Nuvation Bio's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3.190 +0.010    +0.31%
16:00:00 - Closed. Currency in USD ( Disclaimer )
After Hours
3.170
-0.020
-0.627%
16:06:40 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,540,810
  • Bid/Ask: 3.170 / 3.390
  • Day's Range: 3.165 - 3.248
Nuvation Bio 3.190 +0.010 +0.31%

Nuvation Bio Inc Company Profile

 
Get an in-depth profile of Nuvation Bio Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

51

Equity Type

ORD

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company’s lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Contact Information

Address 1500 Broadway Suite 1401
New York, 10036
United States
Phone 332 208 6102
Fax -

Top Executives

Name Age Since Title
David T. Hung 63 2018 Founder, President, CEO & Director
Daniel G. Welch 63 2020 Independent Chairman of the Board
Kim D. Blickenstaff 72 2019 Independent Director
Robert B. Bazemore 56 2020 Independent Director
Wassim Abida - 2023 Member of Scientific Advisory Board
Johann de Bono - 2023 Member of Scientific Advisory Board
Junyuan Wang 51 2024 CEO & Co-Founder of AnHeart Therapeutics and Director
Kathryn E. Falberg 63 2020 Independent Director
Mansoor Raza Mirza 63 2023 Member of Scientific Advisory Board
Robert D. Marshal 64 2024 Independent Director
Allyson J. Ocean 51 2023 Member of Scientific Advisory Board
Xiangmin Cui 56 2024 Director
William Anthony Vernon 68 2019 Independent Director
Gordon B. Mills - 2023 Member of Scientific Advisory Board
Joyce Ann O'Shaughnessy - 2023 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NUVB Comments

Write your thoughts about Nuvation Bio Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Shawn Coker
Shawn Coker Mar 31, 2021 7:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This is definitely a buy right now, 5 analysts rate a strong buy at this level, average target of $20
Be Le
MakingDollars Feb 09, 2021 5:28PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1st.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email